FDMT vs CRSP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FDMT Captures Institutional Edge (3โ1 Pillars ยท 3โ7 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to 4D Molecular Therapeutics, Inc. Common Stock (FDMT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FDMT Revenue | CRSP Revenue | FDMT Op. Margin | CRSP Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -5087.8% | CRSP |
| FY2019 | $10M | $290M | -729.4% | 16.1% | CRSP |
| FY2020 | $10M | $0M | -424.0% | -49295.5% | FDMT |
| FY2021 | $20M | $910M | -395.5% | 40.8% | CRSP |
| FY2022 | $0M | $0M | -3516.5% | -56190.4% | FDMT |
| FY2023 | $20M | $370M | -544.6% | -60.0% | CRSP |
| FY2024 | $0M | $40M | -507678.4% | -1250.4% | CRSP |
| FY2025 | $90M | $0M | -187.2% | -18933.6% | FDMT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FDMT | CRSP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $669.3M | $4.1B | Larger Scale | CRSP |
| Trailing P/E Ratio Valuation | N/M | 23.4x | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | N/M | 23.4x | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +4505.6% | +1325.1% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | -222.7% | -2058.6% | Higher Margin | FDMT |
| Net Profit Margin Profitability | -208.6% | 0.0% | Higher Margin | CRSP |
| Return on Equity (ROE) Capital Efficiency | -56.7% | -25.6% | Higher ROE | CRSP |
| 52-Week Range Position Momentum | 47% ($7โ$17) | 1% ($40โ$63) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 1.89ฮฒ ยท 90% Vol | 1.85ฮฒ ยท 60% Vol | Lower Realized Risk | CRSP |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 48.6 / 100 (HOLD) | Higher Composite | CRSP |